- Article
Synthesis and Biological Evaluation of RGD-Conjugated MEK1/2 Kinase Inhibitors for Integrin-Targeted Cancer Therapy
- Xiaoxiao Li,
- Jianjun Hou,
- Chao Wang,
- Xinjie Liu,
- Hongyan He,
- Ping Xu,
- Zhenjun Yang,
- Zili Chen,
- Yun Wu and
- Lihe Zhang
Two novel series of RGD-MEKI conjugates derived from a MEK1/2 kinase inhibitor—PD0325901—have been developed for integrin receptor mediated anticancer therapy. The first series, alkoxylamine analog RGD-MEKI conjugates 9a–g showed anti-proliferation...